MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $221,000 Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 122.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,048 shares of the company’s stock after buying an additional 5,526 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Teva Pharmaceutical Industries were worth $221,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. LMR Partners LLP bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $1,429,000. Integral Health Asset Management LLC bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $11,020,000. Iron Triangle Partners LP lifted its stake in Teva Pharmaceutical Industries by 13.2% during the fourth quarter. Iron Triangle Partners LP now owns 2,200,036 shares of the company’s stock worth $48,489,000 after purchasing an additional 256,246 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Teva Pharmaceutical Industries by 40.6% during the fourth quarter. Janus Henderson Group PLC now owns 6,737,625 shares of the company’s stock worth $148,497,000 after purchasing an additional 1,945,688 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $332,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Down 4.3%

Shares of NYSE:TEVA opened at $16.77 on Monday. The company has a fifty day moving average of $15.52 and a 200-day moving average of $17.37. The company has a market capitalization of $19.01 billion, a PE ratio of -11.57, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.99 billion. During the same quarter in the previous year, the firm posted $0.48 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on TEVA. Bank of America upped their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a “buy” rating and a $25.00 target price for the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $24.50.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.